HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of sarcoidosis.

Abstract
Not all patients who have sarcoidosis require treatment. For those who require treatment, the outcome of sarcoidosis can be considered conceptually in three broad, and at least partially overlapping, groupings: acute, chronic, and refractory. Although corticosteroids remain the initial drug for most patients who require therapy, several steroid-sparing alternatives have been found effective in treating many aspects of sarcoidosis. Methotrexate is most commonly used cytotoxic agent used for chronic disease, but azathioprine and leflunomide also have been shown to be useful. The tumor necrosis factor antibody infliximab has proved useful in treating refractory sarcoidosis. These various agents led to a treatment strategy for the various aspects of sarcoidosis.
AuthorsRobert P Baughman, Ulrich Costabel, Ronald M du Bois
JournalClinics in chest medicine (Clin Chest Med) Vol. 29 Issue 3 Pg. 533-48, ix-x (Sep 2008) ISSN: 0272-5231 [Print] United States
PMID18539243 (Publication Type: Journal Article, Review)
Topics
  • Combined Modality Therapy (methods, standards)
  • Humans
  • Practice Guidelines as Topic
  • Sarcoidosis (therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: